Benzinga · Sep 1, 2026
Reported Earlier: 'Novo Nordisk launches Wegovy weight-loss pill in Germany' - Reuters
https://www.reuters.com/legal/litigation/novo-nordisk-launches-wegovy-weight-loss-pill-germany-2026-09-01/
NV
NASDAQ · NVO
Novo Nordisk A/S
Healthcare · Drug Manufacturers - General
$46.77
Up+$1.65 (+3.66%)
Updated Sep 3, 2026, 6:34 AM
SID Score
7.3/10
Composite research score
Smart Money
59/100
Neutral
- Market cap
- 223.45B
- P/E ratio
- 12.76
- Dividend yield
- 3.60%
- 52-week range
- $35.12 – $64.16
- Volume
- 13.6M
- Avg. volume
- 16.69M
Price performance
NVO price history
1M range · 21 trading sessions · Daily adjusted prices
NVO closed at $46.77 after 21 trading sessions, up 5.03% for the selected period.
- Last close
- $46.77
- Period change
- +5.03%
- Period low
- $44.53
- Period high
- $48.66
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 2, 2026 | $46.05 | $47.005 | $45.91 | $46.77 | 13.6M |
| Sep 1, 2026 | $45.80 | $46.16 | $45.065 | $45.12 | 9.36M |
| Aug 31, 2026 | $45.28 | $45.61 | $44.95 | $45.33 | 7.61M |
| Aug 28, 2026 | $46.17 | $46.21 | $45.405 | $45.61 | 8.5M |
| Aug 27, 2026 | $45.97 | $46.33 | $45.70 | $46.26 | 13.02M |
| Aug 26, 2026 | $47.80 | $48.04 | $46.87 | $47.19 | 8.88M |
| Aug 25, 2026 | $47.84 | $48.66 | $47.56 | $48.66 | 15.53M |
| Aug 24, 2026 | $47.09 | $47.30 | $46.565 | $46.92 | 9.67M |
| Aug 21, 2026 | $46.35 | $47.165 | $46.34 | $46.74 | 10.91M |
| Aug 20, 2026 | $46.89 | $46.90 | $46.11 | $46.14 | 9.67M |
| Aug 19, 2026 | $46.01 | $47.195 | $45.841 | $46.48 | 19.51M |
| Aug 18, 2026 | $44.91 | $46.065 | $44.76 | $45.71 | 12.09M |
| Aug 17, 2026 | $45.18 | $45.45 | $44.68 | $44.88 | 14.63M |
| Aug 14, 2026 | $46.895 | $47.045 | $45.75 | $45.89 | 10.85M |
| Aug 13, 2026 | $45.96 | $46.785 | $45.73 | $46.72 | 10.19M |
| Aug 12, 2026 | $45.87 | $46.55 | $45.56 | $46.39 | 9.56M |
| Aug 11, 2026 | $47.45 | $47.67 | $46.93 | $47.17 | 7.83M |
| Aug 10, 2026 | $47.00 | $47.735 | $46.66 | $47.73 | 10.19M |
| Aug 7, 2026 | $47.145 | $47.50 | $46.73 | $47.26 | 12.08M |
| Aug 6, 2026 | $45.61 | $45.98 | $44.93 | $45.97 | 13.12M |
| Aug 5, 2026 | $44.81 | $45.72 | $44.38 | $44.53 | 22.28M |
Latest NVO news
The latest Smart Investors Daily articles mentioning NVO.
Stock researchCompany · Overview
NVO research
Overview
Company profile and research snapshot.
Company profile
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $47.50
- Implied upside
- —
- Analysts
- 15
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Buy | — |
| Jul 13, 2026 | BERENBERG | Buy | — |
| Jul 13, 2026 | JYSKE BANK | Hold | — |
| Jul 12, 2026 | GUGGENHEIM SECURITIES LLC | Neutral | — |
| Jul 5, 2026 | EQUISIGHTS | Buy | — |
News briefing
Generated Sep 2, 2026, 9:24 PM
Why Is NVO Up Today?
Novo Nordisk shares gained 3.66% today, driven by positive momentum from the company's expansion of its blockbuster Wegovy weight-loss medication into the German market. While recent analyst commentary has raised questions about valuation, the geographic expansion of GLP-1 products continues to demonstrate strong commercial execution and market demand.
Bottom line: Novo Nordisk's 3.66% gain reflects positive sentiment around Wegovy's German launch and continued execution in the high-growth GLP-1 market, though recent analyst commentary suggests the market remains cautious on valuation and competitive pressures. Investors should monitor international rollout success, competitive dynamics from telehealth players, and supply-chain developments, as these factors will ultimately determine whether the stock can break through resistance levels or remain range-bound despite strong fundamentals.
Benzinga · Sep 1, 2026
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.
SeekingAlpha · Aug 31, 2026
Novo Nordisk: Why The Price Remains Stubbornly Low (Rating Downgrade)
Novo Nordisk (NVO) is under pressure after Q2 2026 results: Wegovy pill gains but sales missed.
SeekingAlpha · Aug 31, 2026
Hims & Hers: A Healthcare Behemoth In The Making
Hims & Hers Health is building a vertically integrated consumer health distribution platform. Read why I am bullish about HIMS stock right now.
AI research layers
Interpretive context generated from the platform’s current data sources.
Novo Nordisk A/S Stock Performance
Novo Nordisk A/S shares closed at $45.12, reflecting mixed momentum across multiple timeframes. Per SID market data, the stock declined 3.72% over the past month and has fallen 19.21% over the trailing twelve months, underperforming the broader healthcare sector. On a three-month basis, however, shares posted a modest gain of 2.86%, suggesting a potential stabilization trend. The stock currently trades below both its 50-day moving average of $47.93 and its 200-day moving average of $46.40, indicating sustained bearish technical positioning. The 14-day relative strength index registers at 41.4, approaching oversold territory but not yet triggering a contrarian buy signal. According to Massive/Polygon data, average daily trading volume stands at approximately 16.69 million shares, reflecting robust liquidity. Novo Nordisk's beta of 0.352 indicates significantly lower volatility relative to the broader market, consistent with its defensive healthcare classification and stable revenue profile.
Novo Nordisk A/S Valuation Analysis
Novo Nordisk A/S currently carries a market capitalization of approximately $223.45 billion, positioning it among the largest healthcare companies globally. Per SID market data, the stock trades at a price-to-earnings ratio of 12.76, which appears modest relative to historical premiums typically commanded by high-growth pharmaceutical names. However, according to SEC filings and derived metrics, the PEG ratio stands at 2.05, suggesting the current valuation may already price in a significant portion of expected growth relative to earnings expansion rates. The price-to-book ratio of 8.43 reflects substantial intangible asset value and brand premium embedded in the company's GLP-1 receptor agonist franchise. Novo Nordisk offers a dividend yield of 3.66%, providing meaningful income return to shareholders. The combination of a below-average P/E ratio with an elevated PEG ratio indicates the market has recalibrated growth expectations downward following the stock's 19.21% decline over the past year.
Smart Money Activity for NVO
Novo Nordisk A/S registers a composite smart money score of 59 out of 100, generating a neutral signal according to SID market data. The institutional component scores a strong 23.0 out of 25, indicating robust positioning among large asset managers and pension funds, consistent with the stock's substantial market capitalization and deep liquidity profile. Per SEC Form 4 filings, the insider activity score stands at 12.5 out of 25, reflecting a moderate level of executive and director transaction activity without a pronounced directional bias. Dark pool activity registers at 11.5 out of 25, suggesting below-average institutional block trading activity in private venues. According to 13F institutional filings, congressional trading interest scores 12.0 out of 25, indicating middling legislative portfolio exposure. The divergence between the high institutional conviction score and the more tepid insider and dark pool readings creates a mixed overall picture, explaining the neutral composite signal despite strong institutional ownership levels among large fund managers.
Novo Nordisk A/S Earnings Outlook
Novo Nordisk A/S faces a concentrated earnings reporting calendar, with four quarterly results scheduled between August 18 and August 28, 2026, according to company earnings reports. Analyst estimates project earnings of $0.81 per American Depositary Share for each of the four upcoming reporting periods, reflecting a consensus expectation for stable sequential profitability. The uniform estimate across all four quarters suggests analysts anticipate consistent operational execution without significant seasonal variance, a pattern consistent with the company's subscription-like chronic disease treatment model. No actual results or earnings surprises are yet available for these periods. The flat earnings trajectory embedded in consensus forecasts aligns with the stock's elevated PEG ratio of 2.05, as analysts appear to model measured growth rather than accelerating expansion. Investors will closely monitor these reports for evidence of GLP-1 franchise momentum, competitive dynamics, and margin trends as the obesity and diabetes therapeutic markets continue evolving rapidly.
Wall Street Analyst Ratings for NVO
Wall Street analyst sentiment toward Novo Nordisk A/S remains predominantly constructive, though recent activity reveals some emerging caution. Per SID consensus data, three of five recent ratings actions maintain Buy recommendations, including reiterations from Rothschild & Co Redburn and Berenberg on July 13, 2026, along with Equisights on July 5, 2026. However, Jyske Bank downgraded the stock from Buy to Hold on July 13, representing the sole negative revision in the recent coverage cycle. Guggenheim Securities LLC maintained its Neutral rating on July 12, 2026, reflecting an unchanged cautious stance. According to Wall Street analyst reports, the distribution yields a 60% Buy, 40% Hold split among the most recent five coverage actions, with zero Sell recommendations outstanding. The Jyske Bank downgrade is notable as it occurred on the same day two other firms reiterated Buy ratings, highlighting growing divergence in analyst views regarding Novo Nordisk's near-term growth trajectory and competitive positioning within the GLP-1 market.
